Laura van 't Veer was honored at an Amsterdam event marking 30 years of molecular diagnostics at the Netherlands Cancer Institute (AVL).
On November 19, 2024, Laura van 't Veer was honored at the special event '30 Years of Molecular Diagnostics at the AVL' held in Amsterdam, commemorating three decades of advances in molecular diagnostics at the Netherlands Cancer Institute (Antoni van Leeuwenhoek, or AVL).
This recognition celebrated van 't Veer's foundational role at the institute, where she served as head of molecular pathology and led the research team that identified the 70-gene signature underlying MammaPrint in 2001. The event brought together colleagues, collaborators, and successors in the field of molecular diagnostics to reflect on how far the discipline had come since the early days of genomic profiling for cancer risk.
Being honored at this milestone event held particular personal and professional significance for van 't Veer, as it took place at the very institution where her groundbreaking research began. It also served as a moment to highlight the institutional legacy she helped build, one that has since trained generations of researchers and clinicians in molecular oncology.
The event underscored the lasting infrastructure and scientific culture that van 't Veer helped establish in the Netherlands, cementing Amsterdam and the AVL as an internationally recognized center for molecular cancer diagnostics.